



- (51) **International Patent Classification:**
C07D 487/04 (2006.01) *A61K 31/519* (2006.01)
A61P 35/00 (2006.01)
- (21) **International Application Number:**
PCT/IB2012/054702
- (22) **International Filing Date:**
10 September 2012 (10.09.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/538,103 22 September 2011 (22.09.2011) US
61/639,639 27 April 2012 (27.04.2012) US
- (71) **Applicant (for all designated States except US):** **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **CHENG, Hengmiao** [US/US]; 16213 Cayenne Ridge Road, San Diego, California 92127 (US). **JOHNSON JR., Theodore Otto** [US/US]; 3612 Torrey View Court, San Diego, California 92130 (US). **KATH, John Charles** [US/US]; 4168 Eastridge, La Mesa, California 91941 (US). **LIU, Kevin Kun-Chin** [US/CN]; Unit 101, Block No. 81, Lane 188, Mingyue Road, Pudong, Shanghai, 200135 (CN). **LUNNEY, Elizabeth Ann** [US/US]; 4205 Calle Mejillones, San Diego, California 92130 (US). **NAGATA, Asako** [JP/US]; 7335 Rock Canyon Drive, San Diego, California 92126 (US). **NAIR, Sajiv Krishnan** [US/US]; 1923 White Birch Drive, Vista, California 92081 (US). **PLANKEN, Simon Paul** [GB/US]; c/o Pfizer Inc., 10555 Science Center Drive, San Diego, California 92121 (US). **SUTTON, Scott Channing** [US/US]; 11660 Weatherwood Place, San Diego, California 92131 (US).

(74) **Agent:** **KLEIMAN, Gabriel L.**; Pfizer Inc., 235 East 42nd Street, New York, New York 10017 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) **Title:** PYRROLOPYRIMIDINE AND PURINE DERIVATIVES



(57) **Abstract:** The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R^1 , R^2 , R^3 , R^4 , R^5 , R^{5a} , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

